BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors.
Phase 1
Completed
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2014-04-08
- Last Posted Date
- 2019-06-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 42
- Registration Number
- NCT02106845
EXPERT, EXPosurE Registry RiociguaT in Patients With Pulmonary Hypertension
- First Posted Date
- 2014-03-20
- Last Posted Date
- 2019-06-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1316
- Registration Number
- NCT02092818
BAY 59-7939 (Xarelto, SPAF), Non Interventional Studies
Completed
- Conditions
- Atrial Fibrillation
- Interventions
- First Posted Date
- 2014-03-18
- Last Posted Date
- 2017-01-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 647
- Registration Number
- NCT02090543
A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy
Phase 1
Completed
- Conditions
- Pediatric Oncology
- Interventions
- First Posted Date
- 2014-03-12
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Bayer
- Target Recruit Count
- 62
- Registration Number
- NCT02085148
Magnetic Resonance Imaging of the Liver in Children 0-2 Months of Age With an Intravenous Injection of Eovist/Primovist Which is a Contrast Agent
Phase 3
Terminated
- Conditions
- Magnetic Resonance Imaging
- Interventions
- First Posted Date
- 2014-03-12
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1
- Registration Number
- NCT02084628
Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
Phase 3
Completed
- Conditions
- Bacterial Infections
- Interventions
- First Posted Date
- 2014-02-19
- Last Posted Date
- 2017-06-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 598
- Registration Number
- NCT02066402
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Phase 3
Completed
- Conditions
- ThromboembolismPulmonary EmbolismThrombosisVenous ThrombosisVenous Thromboembolism
- Interventions
- Drug: BAY 59-7939Drug: ASA
- First Posted Date
- 2014-02-17
- Last Posted Date
- 2017-12-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 3365
- Registration Number
- NCT02064439
Essure (Model ESS310) Placement Rate Study
Phase 3
Completed
- Conditions
- Contraception
- Interventions
- Device: ESS310 (BAY1454032)
- First Posted Date
- 2014-02-17
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 134
- Registration Number
- NCT02064413
- Locations
- 🇺🇸
Tennessee Women's Care, PC, Nashville, Tennessee, United States
🇺🇸Wayne State University Physicians Group, Southfield, Michigan, United States
🇺🇸Mayo Clinic - Rochester, Rochester, Minnesota, United States
Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934
Phase 2
Completed
- Conditions
- Renal Insufficiency, ChronicAnemia
- Interventions
- Biological: Epoetin alfa/betaDrug: Molidustat (BAY85-3934)
- First Posted Date
- 2014-02-17
- Last Posted Date
- 2019-09-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 88
- Registration Number
- NCT02064426
Cardiovascular Disease Risk Factors Prevalence Among Bayer's Employees in São Paulo, Brazil
Completed
- Conditions
- Occupational Health
- Interventions
- Behavioral: Examination and survey
- First Posted Date
- 2014-02-05
- Last Posted Date
- 2016-11-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 361
- Registration Number
- NCT02055651
© Copyright 2025. All Rights Reserved by MedPath